Finally, when administered intraperitoneally, ART inhibited p38, ERK, STAT5, and CREB activation in tumor tissues and the growth of human CML xenograft tumors in mice without exhibiting any significant adverse effects. Here, CREB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.